ADMETlab

The platform provides a batch-processing engine capable of simultaneously predicting over 80 ADMET-related endpoints for a single molecule. This includes key parameters like Caco-2 permeability, CYP450 inhibition for multiple isoforms, hERG cardiotoxicity, and AMES mutagenicity. The systematic approach ensures consistent physicochemical descriptors are used across all models, eliminating the variability introduced by using disparate single-task tools.

Every prediction is accompanied by an applicability domain (AD) assessment, which calculates the chemical similarity of the query molecule to the model's training set. The platform uses a distance-based method to flag predictions that fall outside the reliable region of chemical space. This prevents overconfident extrapolation and provides a critical reliability filter for decision-making, distinguishing ADMETlab from black-box predictors.

The predictive models are built on rigorously curated datasets collected from public databases like ChEMBL and the FDA's Orange Book, as well as peer-reviewed literature. A standardized data cleaning pipeline removes duplicates, resolves activity conflicts, and normalizes units. This focus on data quality over quantity directly addresses the 'garbage in, garbage out' problem common in computational toxicology.

ADMETlab leverages multi-task deep neural networks that learn shared molecular representations across related endpoints. For example, a single model may simultaneously predict inhibition of CYP3A4, CYP2D6, and CYP2C9. This shared representation learning improves generalization, particularly for endpoints with limited data, by leveraging information from related, data-rich tasks.

The platform provides model interpretation using SHAP (SHapley Additive exPlanations) values, which quantify the contribution of each molecular descriptor to a specific prediction. A medicinal chemist can see exactly which substructural features or physicochemical properties are driving a toxicity alert, transforming a black-box prediction into an actionable, interpretable result for lead optimization.

ADMETlab computes a rich set of molecular descriptors, including MACCS keys, Morgan fingerprints (ECFP4), 2D physicochemical properties, and topological descriptors. This multi-view representation ensures that the models capture both local substructural patterns and global molecular properties, providing a robust foundation for predicting diverse ADMET endpoints.

The computational estimation of a drug candidate's Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) properties. This process aims to predict a molecule's pharmacokinetic profile before synthesis, filtering out compounds with poor drug-like properties early in the discovery pipeline.

• Goal: Reduce late-stage attrition due to poor pharmacokinetics
• Input: Molecular structure (SMILES, SDF)
• Output: Predicted values for solubility, permeability, metabolic stability, and toxicity endpoints
• Key Platforms: ADMETlab, SwissADME, ADMET Predictor

The in silico assessment of a compound's potential to block the human Ether-à-go-go-Related Gene (hERG) potassium channel. hERG inhibition can lead to QT interval prolongation, a critical cardiac safety endpoint linked to fatal arrhythmias like Torsades de Pointes.

• Mechanism: Binding to the inner cavity of the hERG channel pore
• Key Features: Lipophilicity (LogP), basicity (pKa), and specific pharmacophores
• Regulatory Impact: A primary reason for drug withdrawal and black-box warnings
• Models: Often uses QSAR, pharmacophore models, or deep learning classifiers

A computational toxicology model that predicts a compound's potential to induce genetic mutations. It is typically benchmarked against the bacterial reverse mutation assay (Ames test) using Salmonella typhimurium strains.

• Endpoint: Binary classification (mutagenic vs. non-mutagenic)
• Structural Alerts: Nitro groups, aromatic amines, epoxides
• Regulatory Requirement: Mandatory for IND applications
• Public Datasets: Hansen benchmark, Carcinogenic Potency Database (CPDB)

A positive prediction is a major red flag in early drug discovery, often triggering structural modification or project termination.

The computational prediction of a drug candidate's potential to inhibit cytochrome P450 enzymes, a superfamily of heme-containing monooxygenases responsible for Phase I metabolism. Inhibition is a major cause of adverse drug-drug interactions (DDIs).

• Key Isoforms: CYP3A4, CYP2D6, CYP2C9, CYP2C19, CYP1A2
• Inhibition Types: Competitive, non-competitive, mechanism-based (time-dependent)
• Time-Dependent Inhibition (TDI): A critical subtype where inhibitory potency increases during pre-incubation due to metabolite formation
• Assay Data: IC50 values from fluorogenic or LC-MS/MS assays

The theoretical region of chemical space within which a predictive model's estimations are reliable. A prediction for a molecule outside this domain is an extrapolation and should be treated with low confidence.

• Definition: Bounded by the structural and property-based similarity to the model's training data
• Methods for Assessment:
  • Bounding Box: Range of individual descriptors
  • Distance-Based: Euclidean or Mahalanobis distance to the training set centroid
  • Density-Based: Probability density estimation of the training distribution
• Importance: Critical for regulatory acceptance of in silico predictions (OECD Principle 3)